The chapter analyzes the efficacy and risks of PCSK9 inhibitors like evolocumab and alirocumab, comparing them to statins in terms of cardiovascular benefits and adverse effects. It delves into the mechanism of action of these drugs, their impact on mortality rates, and the challenges in evaluating their risk versus reward due to limited usage and high cost. The conversation also explores the complexities of assessing cardiovascular risk factors beyond just LDL cholesterol levels, emphasizing a comprehensive approach to improve heart health.

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode